AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine ... rivals Pfizer/BioHaven and their recently-approved Vydura drug.
The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...
The Department of Justice (DoJ) claims that Biohaven – before being ... than $1.8 billion last year. The drug is approved both to treat and prevent migraine in adults and is one of the top ...
The American College of Physicians issues new guidance on the prevention of episodic migraine with pharmacologic treatment recommendations.
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd.
NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
ACP released new clinical guidance on outpatient treatment of acute episodic migraine with combination therapy in patients ...
University of Kansas study finds BPA in plastic containers may trigger migraines. Learn how this common chemical affects your ...
Shares of Biohaven Ltd. (NYSE ... BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials ...
Lasmiditan is a promising treatment for menstrual migraine, offering sustained pain relief comparable to or exceeding that of triptans. However, further research is needed to fully assess its safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback